Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00653822 · ClinicalTrials.gov registry record · Phase 1
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00653822 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 75 participants.
The verdict
NCT00653822, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The objective of this study is to compare the pharmacokinetic and pharmacodynamic properties and safety profile of alefacept in Caucasian and Japanese healthy subjects
Interventions
- DRUG placebo
- DRUG alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00653822
The ClinicalTrials.gov registry entry for NCT00653822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00653822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00653822 about?
NCT00653822 is a clinical study titled "A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers". The objective of this study is to compare the pharmacokinetic and pharmacodynamic properties and safety profile of alefacept in Caucasian and Japanese healthy subjects
What is the current status of trial NCT00653822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2008-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00653822?
The interventions under investigation include: placebo (DRUG), alefacept (DRUG).
Who is sponsoring clinical trial NCT00653822?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.